Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R
Authors
Keywords
miR-375, Insulin-like growth factor 1 receptor, Trastuzumab resistance, erbB2/HER2, Breast cancer
Journal
BMC CANCER
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-02-27
DOI
10.1186/1471-2407-14-134
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
- (2012) A Ward et al. ONCOGENE
- Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells
- (2012) Takehiro Ichikawa et al. PLoS One
- Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer
- (2012) Xiao-Feng Le et al. PLoS One
- Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
- (2011) Joan T. Garrett et al. CANCER BIOLOGY & THERAPY
- MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor
- (2011) Kar Lok Kong et al. GUT
- Up-regulation ofmiR-21Mediates Resistance to Trastuzumab Therapy for Breast Cancer
- (2011) Chang Gong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Gene bi-targeting by viral and human miRNAs
- (2010) Isana Veksler-Lublinsky et al. BMC BIOINFORMATICS
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Characterization of a Candidate Tumor Suppressor Gene Uroplakin 1A in Esophageal Squamous Cell Carcinoma
- (2010) K. L. Kong et al. CANCER RESEARCH
- FoxM1 Mediates Resistance to Herceptin and Paclitaxel
- (2010) Janai R. Carr et al. CANCER RESEARCH
- MicroRNA-375 Is Downregulated in Gastric Carcinomas and Regulates Cell Survival by Targeting PDK1 and 14-3-3
- (2010) Y. Tsukamoto et al. CANCER RESEARCH
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy
- (2010) D. B. Ulanet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer
- (2009) Guohong Hu et al. CANCER CELL
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Therapeutic options for metastatic breast cancer
- (2009) Patrick G Morris et al. EXPERT OPINION ON PHARMACOTHERAPY
- The Promoter of the pri-miR-375 Gene Directs Expression Selectively to the Endocrine Pancreas
- (2009) Tali Avnit-Sagi et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started